Jefferies Group’s PTC Therapeutics PTCT Stock Holding History

Jefferies Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,600	Closed	-$469K	–	1927
2021 Q3	$469K	Buy	+12,600	New	+$518K	﹤0.01%	1252
2020 Q1	–	Sell	-90,000	Closed	-$4.32M	–	2543
2019 Q4	$4.32M	Buy	90,000 +28,833	+47%	+$1.23M	0.03%	600
2019 Q3	$2.07M	Sell	61,167 -18,833	-24%	-$820K	0.02%	1060
2019 Q2	$3.6M	Buy	80,000 +24,343	+44%	+$961K	0.03%	629
2019 Q1	$2.1M	Buy	+55,657	New	+$1.87M	0.02%	896
2018 Q4	–	Sell	-49,912	Closed	-$2.35M	–	2479
2018 Q3	$2.35M	Buy	+49,912	New	+$2.07M	0.02%	904
2018 Q2	–	Sell	-54,523	Closed	-$1.48M	–	2605
2018 Q1	$1.48M	Buy	54,523 +14,523	+36%	+$368K	0.01%	1008
2017 Q4	$667K	Buy	+40,000	New	+$677K	﹤0.01%	1589
2016 Q4	–	Sell	-100,000	Closed	-$1.05M	–	2419
2016 Q3	$1.4M	Buy	+100,000	New	+$813K	0.01%	1105
2015 Q3	–	Sell	-20,141	Closed	-$861K	–	2877
2015 Q2	$969K	Buy	20,141 +9,300	+86%	+$543K	0.01%	1247
2015 Q1	$660K	Buy	+10,841	New	+$661K	﹤0.01%	1257

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jefferies Group's PTCT Position: Q4 2021 in Review

Jefferies Group sold out of PTC Therapeutics (PTCT) in Q4 2021, closing a stake of 12,600 shares — an estimated $469K sold.

Jefferies Group first reported a position in PTCT in Q1 2015 and held it in 11 quarters. The position peaked at $4.32M in Q4 2019. 178 funds tracked by Wall St. Rank hold PTCT as of Q4 2021.

Jefferies Group reported no remaining PTC Therapeutics position as of Q4 2021 after selling out during the quarter.
Jefferies Group sold 12,600 PTC Therapeutics shares in Q4 2021, an estimated $469K.
Jefferies Group first reported a position in PTC Therapeutics in Q1 2015 and held it in 11 quarters.
Jefferies Group's PTC Therapeutics position peaked at $4.32M in Q4 2019.
178 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.